← Alle mensen

EH

Erika Hamilton

10 publicaties

PubMed → Google Scholar →

Publicaties op Oncologisch.com

Abemaciclib Plus Fulvestrant in Gevorderd Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Fase...
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 maart 2025
Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in...
European journal of cancer (Oxford, England : 1990) · 25 februari 2025
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Huma...
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 januari 2025
Imlunestrant als preoperatieve orale SERD bij ER-positief mammacarcinoom: window-studie
Clinical cancer research : an official journal of the American Association for Cancer Research · 2 december 2024
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positi...
The Lancet. Oncology · 2024-11
T-DXd versus T-DM1 bij HER2-positief mammacarcinoom: DESTINY-Breast03 OS
Lancet (London, England) · 14 januari 2023
Trastuzumab deruxtecan versus T-DM1 bij HER2-positief mammacarcinoom: DESTINY-Breast03 fase III
The New England journal of medicine · 24 maart 2022
Abemaciclib plus endocriene therapie als adjuvant bij HR+/HER2- klierpositief mammacarcinoom: monarchE fase III
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 december 2020
Intracraniële werkzaamheid en overleving met tucatinib bij HER2-positief mammacarcinoom: HER2CLIMB CZS-analyse
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 augustus 2020
Tucatinib plus trastuzumab-capecitabine bij HER2-positief gemetastaseerd mammacarcinoom: HER2CLIMB fase III
The New England journal of medicine · 13 februari 2020